美股新聞 標題聯播 · 近 24 小時 284 則 · 25 個來源 · 最新 9/20 06:32
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · NTLA近 30 天 11 則 · 第 1 / 1 頁
- 體內基因編輯市場規模、佔有率及趨勢分析 - 全球機會分析與產業預測 (2026-2036)In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
- Intellia 的產品線進展能否在競爭中創造長期價值？Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
- 基因編輯巨頭及其競爭對手飆升 邁向突破Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
- Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
- FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
- Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
- Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
- Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
- Sector Update: Healthcare Stocks Decline Friday Afternoon
- Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
- Cathie Wood's ARK Goes On $27 Million SpaceX Shopping Spree
- Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。